| 20.14 -11.85 (-37.04%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 32.42 |
1-year : | 38 |
| Resists | First : | 27.76 |
Second : | 32.54 |
| Pivot price | 30.12 |
|||
| Supports | First : | 20.03 |
Second : | 16.66 |
| MAs | MA(5) : | 28.91 |
MA(20) : | 29.97 |
| MA(100) : | 25.11  |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 55.1 |
D(3) : | 67.5 |
| RSI | RSI(14): 26.7 |
|||
| 52-week | High : | 32.7 | Low : | 8.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BBNX ] has closed below the lower bollinger band by 37.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 80.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 23.94 - 24.06 | 24.06 - 24.14 |
| Low: | 19.78 - 19.92 | 19.92 - 20.01 |
| Close: | 19.94 - 20.15 | 20.15 - 20.28 |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Fri, 09 Jan 2026
Beta Bionics stock tumbles following deceleration in new patient starts - Investing.com
Fri, 09 Jan 2026
Analysts downgrade Beta Bionics on new patient starts miss - Drug Delivery Business
Fri, 09 Jan 2026
Beta Bionics stock to exceed Q4 revenue targets, Stifel maintains Buy - Investing.com
Fri, 09 Jan 2026
BofA Securities downgrades Beta Bionics stock to Neutral on valuation concerns - Investing.com
Thu, 08 Jan 2026
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics - The Manila Times
Wed, 07 Jan 2026
Insider Sell: Mike Mensinger Sells 2,200 Shares of Beta Bionics Inc (BBNX) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Equipment & Services
|
|
| Shares Out | 44 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 10.4 (%) |
| Held by Institutions | 110.5 (%) |
| Shares Short | 4,020 (K) |
| Shares Short P.Month | 3,570 (K) |
| EPS | -1.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.69 |
| Profit Margin | -87.9 % |
| Operating Margin | -62.6 % |
| Return on Assets (ttm) | -20.1 % |
| Return on Equity (ttm) | -47.6 % |
| Qtrly Rev. Growth | 63 % |
| Gross Profit (p.s.) | 1.09 |
| Sales Per Share | 2.01 |
| EBITDA (p.s.) | -1.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -10.39 |
| PEG Ratio | 0 |
| Price to Book value | 3 |
| Price to Sales | 10 |
| Price to Cash Flow | -15.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|